Celia Marginean

ORCID: 0000-0002-3608-423X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Gastric Cancer Management and Outcomes
  • Pancreatic and Hepatic Oncology Research
  • Colorectal Cancer Treatments and Studies
  • Genetic factors in colorectal cancer
  • Vascular Tumors and Angiosarcomas
  • Tuberous Sclerosis Complex Research
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Colorectal Cancer Surgical Treatments
  • Gallbladder and Bile Duct Disorders
  • Cancer Genomics and Diagnostics
  • Histiocytic Disorders and Treatments
  • Ovarian cancer diagnosis and treatment
  • Hedgehog Signaling Pathway Studies
  • Pancreatitis Pathology and Treatment
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Genetic and Kidney Cyst Diseases
  • Renal and related cancers
  • Gastrointestinal Tumor Research and Treatment
  • Colorectal Cancer Screening and Detection
  • Cancer Immunotherapy and Biomarkers
  • Vascular Malformations and Hemangiomas
  • Colorectal and Anal Carcinomas
  • Fibroblast Growth Factor Research
  • Urinary and Genital Oncology Studies
  • Infectious Disease Case Reports and Treatments

St. Luke's Hospital
2024

Baylor College of Medicine
2022-2024

Providence Portland Medical Center
2020

Ottawa Hospital
2008-2018

University of Ottawa
2008-2018

Ottawa Hospital Research Institute
2011-2016

Flinders Medical Centre
2013

Goodwin (United Kingdom)
2013

Sunnybrook Health Science Centre
2013

Health Sciences Centre
2013

Cetuximab improves survival in patients with K-ras wild-type advanced colorectal cancer. We examined the predictive and prognostic significance of additional biomarkers this setting, particular BRAF, PIK3CA, PTEN.Available tumor samples were analyzed from CO.17 study. BRAF mutations identified tumor-derived DNA by direct sequencing PIK3CA using a high-resolution melting screen confirmation sequencing. PTEN expression immunohistochemistry (IHC) was performed on tissue microarrays. For each...

10.1158/1078-0432.ccr-13-0606 article EN Clinical Cancer Research 2013-11-12

Hepatic small vessel neoplasm (HSVN) is a recently described infiltrative vascular of the liver, composed vessels. Although nature can mimic angiosarcoma, HSVN are thought to be benign or low-grade neoplasms because they lack cytologic atypia and increased proliferation. To characterize molecular pathogenesis HSVN, we performed both targeted panel sequencing exome on 18 in liver including 8 6 classic cavernous hemangioma (CH), 4 variant lesions (VL) with overlapping features between CH. All...

10.1097/pas.0000000000001110 article EN The American Journal of Surgical Pathology 2018-07-03

Undifferentiated carcinoma refers to an epithelial malignancy that lacks morphological evidence of differentiation. Recent studies have implicated the loss constitutively expressed switch/sucrose non-fermenting (SWI/SNF) complex subunits in undifferentiated carcinomas gastrointestinal tract and other sites. In this study we examine expression SWI/SNF mismatch repair (MMR) proteins a series from pancreas.We searched pathology databases four Canadian health centres for primary pancreatic...

10.1111/his.14096 article EN Histopathology 2020-05-15

Aims Following the introduction of colorectal cancer screening programmes throughout Canada, it became necessary to standardise diagnosis adenomas. Canadian guidelines for standardised reporting adenomas were developed in 2011. The aims present study (a) assess interobserver variability classification dysplasia and architecture (b) determine if could be improved by adoption criteria specified national guidelines. Methods An a priori power analysis was used an adequate number cases...

10.1136/jclinpath-2014-202177 article EN Journal of Clinical Pathology 2014-07-08

Mucinous cystic neoplasms of the liver (hepatobiliary cystadenomas) are rare neoplastic lesions. Such cysts often incorrectly diagnosed and managed, carry a risk malignancy. The objective this study was to review surgical experience with these lesions over 15 years.A retrospective chart identified consecutive patients undergoing surgery for cystadenomas from 1997-2011. Clinical data were collected summarized.Thirteen (mean age 51 years, 12/13 females) 4.6-18.1 cm identified. Most located in...

10.1111/hpb.12026 article EN publisher-specific-oa HPB 2012-12-07

Extramammary Paget disease (EMPD) involving the perianal region is rare and challenging to manage. Primary EMPD involves stand-alone noninvasive lesions within epidermis, while secondary phenotypically similar derived from separate underlying malignancies. Differentiating between primary when no malignancies are detected during workup. Continued reporting of cases encouraged so that risk stratification can be improved patients managed with an appropriate level aggressiveness. Herein, we...

10.1159/000457789 article EN cc-by-nc Case Reports in Gastroenterology 2017-03-03

In recent years, significant advances have been made in the management of metastatic colorectal cancer. Traditionally, an improvement overall survival has considered “gold standard”—the most convincing measure efficacy. However, requires larger patient numbers and longer follow-up may often be confounded by other factors, including subsequent therapies crossover. Given number active for potential investigation, demand rapid evaluation early availability new is growing. Progression-free...

10.3747/co.v18is2.941 article EN cc-by Current Oncology 2011-10-01

Background: Previous studies indicate that drugs targeting the Epidermal Growth Factor Receptor (EGFR) signaling pathways can induce objective responses, prolong time to progression and improve survival of patients with metastatic colorectal cancer (mCRC). EGFR expression in primary tumour may not predict response these agents data is conflicting regarding correlation site. In other sites, presence mutations was associated efficacy a subset patients.Objectives: The goal this study correlate...

10.4161/cbt.10.5.12610 article EN Cancer Biology & Therapy 2010-09-01

Hepatocellular carcinoma (HCC) is an uncommon tumour, but its incidence increasing in Canada and elsewhere. Currently, there are no Canadian recommendations for diagnosis treatment of hcc, possible options may have regional limitations. A consensus symposium was held the Ottawa region to consider current diagnostic management hcc. These were developed: Diagnosis-with adequate imaging, a biopsy not required pre-surgery, before start systemic therapy; lesions smaller than 1 cm should be...

10.3747/co.v17i2.555 article EN Current Oncology 2010-04-01

Research Articles| February 15 2011 Immunostaining as a Diagnostic Aid in Cytopathologic Study of Upper Urinary Tract Urothelial Carcinoma Subject Area: Pathology and Cell Biology Kien T. Mai; Mai From the Division Anatomical Pathology, Department Laboratory Medicine, The Ottawa Hospital, University Ottawa, Ontario, Canada; New York Medical College, York, U.S.A. Search for other works by this author on: This Site PubMed Google Scholar Iris Teo; Teo Susan J. Robertson; Robertson Celia...

10.1159/000325400 article EN Acta Cytologica 2009-01-01

The annual Eastern Canadian Gastrointestinal Cancer Consensus Conference 2017 was held in St. John's, Newfoundland and Labrador, 28-30 September. Experts radiation oncology, medical surgical cancer genetics who are involved the management of patients with gastrointestinal malignancies participated presentations discussion sessions for purpose developing recommendations presented here. This consensus statement addresses multiple topics gastric, rectal, colon cancer, including ■ identification...

10.3747/co.25.4083 article EN Current Oncology 2018-08-01

The annual Eastern Canadian Colorectal Cancer Consensus Conference was held in Halifax, Nova Scotia, October 20-22, 2011. Health care professionals involved the of patients with colorectal cancer participated presentation and discussion sessions for purposes developing recommendations presented here. This consensus statement addresses current issues management rectal cancer, including pathology reporting, neoadjuvant systemic radiation therapy, surgical techniques, palliative patients. Other...

10.3747/co.20.1638 article EN cc-by Current Oncology 2013-10-01

Inflammatory oesophageal pseudotumours are rare lesions, thought to be reactive. Due marked atypia of the stromal cells, these can misdiagnosed as malignancies. The objective this study was characterize histological and immunohistochemical features a series inflammatory oesophagus.We present 12 cases pseudotumours, occurring in seven females five males, with mean age 57.3 years. Clinical presentations were variable; dysphagia, abdominal pain weight loss upper gastrointestinal bleed. In...

10.1111/his.12615 article EN Histopathology 2014-11-13

ABSTRACT Glomus tumors are benign vascular soft tissue neoplasms of glomus bodies. Primary lung rare and usually express smooth muscle markers, negative for cytokeratin neuroendocrine markers in immunohistochemistry. We report a case primary tumor showing diffuse, strong, aberrant immunoexpression synaptophysin morphologically mimicking low‐grade (carcinoid tumor).

10.1002/dc.25439 article EN Diagnostic Cytopathology 2024-12-29

Objectives: Serous and mucinous cystic neoplasms (SCNs/MCNs) are the most common true of pancreas occur more frequently in women. The aim this study was to characterize stroma SCNs compare its phenotype with that MCNs. Methods: A total 12 5 MCNs were analyzed immunohistochemically using following antisera: progesterone receptor (PR), estrogen (ER), inhibin, CD10, vimentin. Normal pancreatic tissue (17 cases) ductal adenocarcinomas (3 used as controls. Results: Eight patients all For SCNs,...

10.1097/mpa.0b013e3181f74c23 article EN Pancreas 2010-09-29

3515 Background: CET, a monoclonal antibody targeting the epidermal growth factor receptor, improves overall survival (OS) and progression free (PFS) in patients (pts) with KRAS wild-type (WT) chemotherapy refractory CRC. BRAF PIK3CA mutation status, PTEN expression levels may further predict benefit from CET therapy. Methods: Available colorectal tumour samples were analyzed phase III trial of plus best supportive care (BSC) vs BSC alone (NEJM 2007; 357(20)). mutations (MUT) identified...

10.1200/jco.2012.30.15_suppl.3515 article EN Journal of Clinical Oncology 2012-05-20
Coming Soon ...